These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
126 related articles for article (PubMed ID: 37768313)
1. Examining the activity of cefepime-taniborbactam against Mojica MF; Zeiser ET; Becka SA; LiPuma JJ; Six DA; Moeck G; Papp-Wallace KM Antimicrob Agents Chemother; 2023 Nov; 67(11):e0049823. PubMed ID: 37768313 [TBL] [Abstract][Full Text] [Related]
2. "Switching Partners": Piperacillin-Avibactam Is a Highly Potent Combination against Multidrug-Resistant Zeiser ET; Becka SA; Wilson BM; Barnes MD; LiPuma JJ; Papp-Wallace KM J Clin Microbiol; 2019 Aug; 57(8):. PubMed ID: 31167848 [TBL] [Abstract][Full Text] [Related]
3. Activity of Imipenem-Relebactam against Multidrug- and Extensively Drug-Resistant Burkholderia cepacia Complex and Burkholderia gladioli. Becka SA; Zeiser ET; LiPuma JJ; Papp-Wallace KM Antimicrob Agents Chemother; 2021 Oct; 65(11):e0133221. PubMed ID: 34370574 [TBL] [Abstract][Full Text] [Related]
4. In vitro comparative activity of the new beta-lactamase inhibitor taniborbactam with cefepime or meropenem against Klebsiella pneumoniae and cefepime against Pseudomonas aeruginosa metallo-beta-lactamase-producing clinical isolates. Meletiadis J; Paranos P; Georgiou PC; Vourli S; Antonopoulou S; Michelaki A; Vagiakou E; Pournaras S Int J Antimicrob Agents; 2021 Nov; 58(5):106440. PubMed ID: 34551356 [TBL] [Abstract][Full Text] [Related]
5. In vitro activity of the novel β-lactamase inhibitor taniborbactam (VNRX-5133), in combination with cefepime or meropenem, against MDR Gram-negative bacterial isolates from China. Wang X; Zhao C; Wang Q; Wang Z; Liang X; Zhang F; Zhang Y; Meng H; Chen H; Li S; Zhou C; Li H; Wang H J Antimicrob Chemother; 2020 Jul; 75(7):1850-1858. PubMed ID: 32154866 [TBL] [Abstract][Full Text] [Related]
6. The Next-Generation β-Lactamase Inhibitor Taniborbactam Restores the Morphological Effects of Cefepime in KPC-Producing Escherichia coli. Roach EJ; Uehara T; Daigle DM; Six DA; Khursigara CM Microbiol Spectr; 2021 Oct; 9(2):e0091821. PubMed ID: 34494877 [TBL] [Abstract][Full Text] [Related]
7. VNRX-5133 (Taniborbactam), a Broad-Spectrum Inhibitor of Serine- and Metallo-β-Lactamases, Restores Activity of Cefepime in Hamrick JC; Docquier JD; Uehara T; Myers CL; Six DA; Chatwin CL; John KJ; Vernacchio SF; Cusick SM; Trout REL; Pozzi C; De Luca F; Benvenuti M; Mangani S; Liu B; Jackson RW; Moeck G; Xerri L; Burns CJ; Pevear DC; Daigle DM Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31871094 [TBL] [Abstract][Full Text] [Related]
9. Overcoming an Extremely Drug Resistant (XDR) Pathogen: Avibactam Restores Susceptibility to Ceftazidime for Burkholderia cepacia Complex Isolates from Cystic Fibrosis Patients. Papp-Wallace KM; Becka SA; Zeiser ET; Ohuchi N; Mojica MF; Gatta JA; Falleni M; Tosi D; Borghi E; Winkler ML; Wilson BM; LiPuma JJ; Nukaga M; Bonomo RA ACS Infect Dis; 2017 Jul; 3(7):502-511. PubMed ID: 28264560 [TBL] [Abstract][Full Text] [Related]
10. Assessment of Activity and Resistance Mechanisms to Cefepime in Combination with the Novel β-Lactamase Inhibitors Zidebactam, Taniborbactam, and Enmetazobactam against a Multicenter Collection of Carbapenemase-Producing Vázquez-Ucha JC; Lasarte-Monterrubio C; Guijarro-Sánchez P; Oviaño M; Álvarez-Fraga L; Alonso-García I; Arca-Suárez J; Bou G; Beceiro A; Antimicrob Agents Chemother; 2022 Feb; 66(2):e0167621. PubMed ID: 34807754 [TBL] [Abstract][Full Text] [Related]
11. In vivo pharmacodynamics of new-generation β-lactamase inhibitor taniborbactam (formerly VNRX-5133) in combination with cefepime against serine-β-lactamase-producing Gram-negative bacteria. Abdelraouf K; Almarzoky Abuhussain S; Nicolau DP J Antimicrob Chemother; 2020 Dec; 75(12):3601-3610. PubMed ID: 32862218 [TBL] [Abstract][Full Text] [Related]
12. Potent inhibitory activity of taniborbactam towards NDM-1 and NDM-1 Piccirilli A; Segatore B; Brisdelli F; Amicosante G; Perilli M Int J Antimicrob Agents; 2021 Jan; 57(1):106228. PubMed ID: 33246038 [TBL] [Abstract][Full Text] [Related]
13. Major Aspects of Burkholderia gladioli and Burkholderia cepacia Infections in Children. Bedir Demirdag T; Ozkaya Parlakay A; Aygar IS; Gulhan B; Kanik Yuksek S Pediatr Infect Dis J; 2020 May; 39(5):374-378. PubMed ID: 32118858 [TBL] [Abstract][Full Text] [Related]
14. Activity of Cefepime in Combination with the Novel β-Lactamase Inhibitor Taniborbactam (VNRX-5133) against Extended-Spectrum-β-Lactamase-Producing Isolates in Kloezen W; Melchers RJ; Georgiou PC; Mouton JW; Meletiadis J Antimicrob Agents Chemother; 2021 Mar; 65(4):. PubMed ID: 33431413 [TBL] [Abstract][Full Text] [Related]
15. Assessing the Potency of β-Lactamase Inhibitors with Diverse Inactivation Mechanisms against the PenA1 Carbapenemase from Nukaga M; Yoon MJ; Taracilia MA; Hoshino T; Becka SA; Zeiser ET; Johnson JR; Papp-Wallace KM ACS Infect Dis; 2021 Apr; 7(4):826-837. PubMed ID: 33723985 [No Abstract] [Full Text] [Related]
16. In vitro activity of seven β-lactams including ceftolozane/tazobactam and ceftazidime/avibactam against Burkholderia cepacia complex, Burkholderia gladioli and other non-fermentative Gram-negative bacilli isolated from cystic fibrosis patients. Massip C; Mathieu C; Gaudru C; Miaut V; Floch P; Oswald E; Segonds C; Guet-Revillet H J Antimicrob Chemother; 2019 Feb; 74(2):525-528. PubMed ID: 30312409 [No Abstract] [Full Text] [Related]
17. Exploring the Role of the Ω-Loop in the Evolution of Ceftazidime Resistance in the PenA β-Lactamase from Burkholderia multivorans, an Important Cystic Fibrosis Pathogen. Papp-Wallace KM; Becka SA; Taracila MA; Zeiser ET; Gatta JA; LiPuma JJ; Bonomo RA Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27872073 [TBL] [Abstract][Full Text] [Related]
19. The Class A β-Lactamase Produced by Becka SA; Zeiser ET; LiPuma JJ; Papp-Wallace KM Antibiotics (Basel); 2022 May; 11(5):. PubMed ID: 35625319 [TBL] [Abstract][Full Text] [Related]
20. Hernández-García M; García-Castillo M; Ruiz-Garbajosa P; Bou G; Siller-Ruiz M; Pitart C; Gracia-Ahufinger I; Mulet X; Pascual Á; Tormo N; Cantón R Antimicrob Agents Chemother; 2022 Mar; 66(3):e0216121. PubMed ID: 35007130 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]